Pyxis Oncology (PYXS) EBITDA Margin (2024 - 2025)

Pyxis Oncology's (PYXS) quarterly EBITDA Margin came in at 165.75% in Q4 2025, up 76.33% on a QoQ basis from 700.35% in Q2 2025.

Pyxis Oncology (PYXS) EBITDA Margin (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has 2 years of EBITDA Margin data on file, last reported at 165.75% in Q4 2025.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 165.75% in Q4 2025; TTM through Dec 2025 was 609.18%, a 5511.0% decrease from a year earlier, with the FY2025 full-year figure at 609.18%, down 5511.0% from the prior year.
EBITDA Margin for Q4 2025 stood at 165.75%, up from 700.35% in the prior quarter.
Over the last five years, EBITDA Margin for PYXS reached as high as 34.71% in Q1 2024 and fell as low as 700.35% in Q2 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Pyxis Oncology	166.54 Mn	99.69 Mn	8.65 Mn	-165.75%

Historic Data

Download Data

Date	Value
Dec 31, 2025	-165.75%
Jun 30, 2025	-700.35%
Mar 31, 2024	-34.71%